Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Principia Biopharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Principia Biopharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Principia Biopharma's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
Principia Biopharma's revenue is expected to grow by 4.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Principia Biopharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Principia Biopharma's finances.
The net worth of a company is the difference between its assets and liabilities.
Principia Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Principia Biopharma's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Principia Biopharma's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Principia Biopharma has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Martin Babler, also known as Matt, PhD serves as the Chief Executive Officer of Principia Biopharma Inc since April 2011. Mr. Babler served as the Chief Executive Officer and President of Talima Therapeutics Inc. since December 2007. He served as Senior Executive at Genentech where he served in various management positions for the past eight years. He served as Vice President of Immunology Sales and Marketing of Genentech Inc. since June 2004. He joined Genentech in 1998 as a Director of Cardiovascular Marketing. During the next several years, he held positions as a Director and a Senior Director of Commercial Development and a Senior Director of Immunology Sales and Marketing. Mr. Babler was responsible for leading the strategic direction of the Immunology commercial area, including the management of sales and marketing efforts for Xolair(R) (Omalizumab) and market preparation for Rituxan(R) (Rituximab) for immune system disorders and product line extensions. He held several positions of increasing responsibility at Eli Lilly and Company. He serves as a Director of the Chief Executive Officer of Principia Biopharma Inc. He served as a Director of ZS Pharma, Inc. from February 10, 2015 to December 16, 2015. He served as a Director of Talima Therapeutics, Inc. He served as Director of Infinity Pharmaceuticals, Inc. since May 2008 until March 6, 2014. Mr. Babler completed basic and advanced studies in pharmaceutical science and received a degree in Pharmacy from the Swiss Federal Institute of Technology in Zurich, Switzerland. Mr. Babler is a graduate of the Executive Development Program at the Kellogg Graduate School of Management.
Insufficient data for Matt to compare compensation growth.
Matt's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Principia Biopharma management team is about average.
Executive Chairman of the Board
CEO & Director
Chief Financial Officer
Chief Development Officer
Chief Scientific Officer
Chief Business Officer
Vice President of Human Resources
Chief Medical Officer
Senior Vice President of Development Operations
Senior VP of Commercial & Project Team Leader
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Principia Biopharma board of directors is less than 3 years, this suggests a new board.
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.